DK2335074T3 - Individuel optimering af 5-fluoruracildosis ved folfox-behandling - Google Patents
Individuel optimering af 5-fluoruracildosis ved folfox-behandlingInfo
- Publication number
- DK2335074T3 DK2335074T3 DK08875930.3T DK08875930T DK2335074T3 DK 2335074 T3 DK2335074 T3 DK 2335074T3 DK 08875930 T DK08875930 T DK 08875930T DK 2335074 T3 DK2335074 T3 DK 2335074T3
- Authority
- DK
- Denmark
- Prior art keywords
- fluoruracil
- dosage
- individual optimization
- folfox treatment
- folfox
- Prior art date
Links
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 title 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title 1
- 229960002949 fluorouracil Drugs 0.000 title 1
- 238000005457 optimization Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2008/055625 WO2010035075A1 (en) | 2008-09-26 | 2008-09-26 | Individual 5-fluorouracile dose optimization in folfox treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2335074T3 true DK2335074T3 (da) | 2013-06-17 |
Family
ID=40626871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08875930.3T DK2335074T3 (da) | 2008-09-26 | 2008-09-26 | Individuel optimering af 5-fluoruracildosis ved folfox-behandling |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110246079A1 (da) |
| EP (1) | EP2335074B1 (da) |
| JP (1) | JP2012503639A (da) |
| AU (1) | AU2008362108B2 (da) |
| CA (1) | CA2738753C (da) |
| DK (1) | DK2335074T3 (da) |
| ES (1) | ES2414505T3 (da) |
| RU (1) | RU2482496C2 (da) |
| WO (1) | WO2010035075A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010035076A1 (en) * | 2008-09-26 | 2010-04-01 | Centre Regional De Lutte Contre Le Cancer D'angers | Individual 5-fluorouracile dose optimization in folfiri treatment |
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| JP7122256B2 (ja) * | 2017-02-14 | 2022-08-19 | アイソフォル・メディカル・エービー | 血漿２’－デオキシウリジン（ｄＵｒｄ）の増加およびチミジル酸合成酵素阻害のための方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005231436A1 (en) * | 2004-04-02 | 2005-10-20 | Adventrx Pharmaceuticals, Inc. | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
| FR2884257B1 (fr) * | 2005-04-12 | 2010-11-26 | Centre Regional De Lutte Contre Le Cancer Dangers | Prevention des toxicites dues au 5-fluorouracile |
| RU2297630C1 (ru) * | 2005-10-04 | 2007-04-20 | Общество с ограниченной ответственностью "Витальные системы+" | Способ определения концентрации лекарственного препарата в биологических средах человека при лечении онкологических больных |
-
2008
- 2008-09-26 ES ES08875930T patent/ES2414505T3/es active Active
- 2008-09-26 WO PCT/IB2008/055625 patent/WO2010035075A1/en active Application Filing
- 2008-09-26 US US13/121,116 patent/US20110246079A1/en not_active Abandoned
- 2008-09-26 EP EP08875930A patent/EP2335074B1/en active Active
- 2008-09-26 RU RU2011112494/15A patent/RU2482496C2/ru not_active IP Right Cessation
- 2008-09-26 AU AU2008362108A patent/AU2008362108B2/en not_active Ceased
- 2008-09-26 CA CA2738753A patent/CA2738753C/en active Active
- 2008-09-26 DK DK08875930.3T patent/DK2335074T3/da active
- 2008-09-26 JP JP2011528434A patent/JP2012503639A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2335074B1 (en) | 2013-03-20 |
| AU2008362108A1 (en) | 2010-04-01 |
| EP2335074A1 (en) | 2011-06-22 |
| CA2738753A1 (en) | 2010-04-01 |
| US20110246079A1 (en) | 2011-10-06 |
| JP2012503639A (ja) | 2012-02-09 |
| RU2011112494A (ru) | 2012-11-10 |
| CA2738753C (en) | 2018-11-06 |
| RU2482496C2 (ru) | 2013-05-20 |
| AU2008362108B2 (en) | 2015-09-03 |
| WO2010035075A1 (en) | 2010-04-01 |
| ES2414505T3 (es) | 2013-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2222272T3 (da) | Behandling af luftvejssygdom | |
| DK3289876T3 (da) | Forbindelser til behandling af cancer | |
| EP2451518A4 (en) | MASK WITH MULTIPLE ROOMS | |
| EP2558115A4 (en) | METHOD FOR THE TREATMENT OF METABOLISM INTERFERENCE BY FGF | |
| DK3470063T3 (da) | Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme | |
| EP2310006A4 (en) | CANCER TREATMENT | |
| EP2473054A4 (en) | COMPOSITIONS AND METHODS OF TREATING LEUKEMIA | |
| DK2500017T3 (da) | Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse | |
| EP2223788A4 (en) | CUT PROCESSING MECHANISM | |
| DK2709453T3 (da) | Anvendelse af thiazolid-forbindelser til forebyggelse og behandling af virussygdomme, cancer og sygdomme forårsaget af intracellulære infektioner | |
| EP2234926A4 (en) | CHAMBER FOR TREATMENT WITH ULTRAVIOLETTEM LIGHT | |
| BRPI0917883A2 (pt) | Métodos e compostos para o tratamento e prevenção da doença citrus greening | |
| LT2318188T (lt) | Medienos plokštės apdorojimo būdas | |
| DK3276004T3 (da) | Fremgangsmåder til behandling af kronisk nyresygdom | |
| DK2506712T3 (da) | Morfinanderivater til behandling af lægemiddeloverdosering | |
| DK2872497T4 (da) | Chromanyl-derivater til behandling af mitokondriel sygdom | |
| DK2627345T3 (da) | Formuleringer til behandling af sygdomme i de øvre luftveje | |
| HUS1600039I1 (hu) | Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával | |
| EP1987838A4 (en) | NEW CONNECTION TO TUMOR THERAPY | |
| DK2252317T3 (da) | Behandling af makuladegeneration | |
| EP2247297A4 (en) | THERAPEUTIC TREATMENT OF LUNG DISEASES | |
| BRPI0909270A2 (pt) | Compostos de sirna para inibição de rtp801 | |
| EP2381944A4 (en) | ANTIVIRAL COMPOUNDS, TREATMENT AND ASSAY | |
| HK1161837A1 (en) | Use of nifuratel to treat infections caused by atopobium species | |
| BRPI0822264A2 (pt) | Dapsona para tratar rosácea |